Hyperbaric Oxygen Stimulation for Patients With Brain Malignancies After Radiation Therapy.
NCT01808625 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2
Last updated 2017-05-30
Summary
Radiotherapy is the mainstay of treatment for brain malignancies and is associated with significant neurotoxicity. Due to continuous increase in patient's survival, the long term risk for radiation-induced brain inflammation and necrosis inducing secondary cognitive impairments are increasing concerns. Currently there is no effective treatment for preventing long term radiation-induced brain damage.
Hyperbaric oxygen therapy (HBOT) is the administration of high oxygen concentrations within a pressurized chamber to increase the cellular/mitochondrial delivery of oxygen. Oxygen stimulation by HBOT has become the definitive therapy for radiation-induced damage to soft tissues and bone due to its ability to stimulate healing processes by supplying the energy/oxygen needed while down-regulating genes involved in inflammation. Oxygen stimulation by HBOT is currently indicated for patients with overt radiation-induced neurotoxicity and was proven to reduce further development of radiation damage while stimulating "idling" neurons to return to function. Since HBOT is considered safe, we hypothesize that its application following radiation, before the manifestation of neurological side effects, may help avert development of early/delayed onset radiation-induced neurotoxicity.
In the proposed study, for the first time, HBOT will be applied early after radiation to prevent the expected decrease in patients neurocognitive functions (NCF) and improve their quality of life (QOL). The study is designed to provide statistically significant assessment, in a prospective randomized clinical trial, of the effect of oxygen stimulation applied soon after brain radiotherapy, for patients with primary and secondary brain tumors, on patients QOL and NCF. In addition, advanced imaging methodologies will be applied to study the feasibility of quantifying oxygen stimulation effects on the tumor and surrounding brain tissue.
Conditions
- BRAIN MALIGNANCIES AFTER RADIATION THERAPY
Interventions
- OTHER
-
HYPERBARIC OXYGEN STIMULATION
30 daily sessions, 6 days a week of 90 min exposure to 100% oxygen at 2 ATA.
Sponsors & Collaborators
-
Assaf-Harofeh Medical Center
collaborator OTHER_GOV -
Sheba Medical Center
lead OTHER_GOV
Principal Investigators
-
Leor Zach, MD · Sheba Medical Center
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-03-31
- Primary Completion
- 2018-01-31
- Completion
- 2019-01-31
Countries
- Israel
Study Locations
More Related Trials
-
Radiation Therapy Followed by Bleomycin in Treating Adult Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
NCT00006916 ·Status: TERMINATED ·Phase: PHASE2
-
Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme
NCT00002545 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Recurrent Brain Tumors: Metabolic Manipulation Combined With Radiotherapy
NCT02149459 ·Status: UNKNOWN ·Phase: PHASE1
-
Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors
NCT00389584 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery
NCT01372774 ·Status: COMPLETED ·Phase: PHASE3
-
Hippocampal-Avoiding Whole Brain Irradiation With Simultaneous Integrated Boost for Treatment of Brain Metastases
NCT01414738 ·Status: COMPLETED ·Phase: PHASE2
-
Radiation Therapy in Treating Patients With Brain Cancer
NCT00002620 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma
NCT06016452 ·Status: RECRUITING ·Phase: PHASE2
-
Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma
NCT00936052 ·Status: UNKNOWN ·Phase: PHASE2
-
Supportive Care With or Without Repeated Whole Brain Radiotherapy in Patients With Recurrent Brain Metastases
NCT04084431 ·Status: WITHDRAWN ·Phase: NA
-
Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00099125 ·Status: COMPLETED ·Phase: PHASE2
-
Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00053183 ·Status: COMPLETED ·Phase: PHASE1
-
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
NCT00096265 ·Status: TERMINATED ·Phase: PHASE3
-
Hypofractionated Radiation Therapy for Glioblastoma
NCT03212235 ·Status: UNKNOWN ·Phase: PHASE2
-
Pilot Phase 2 Study Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases
NCT03189381 ·Status: TERMINATED ·Phase: NA
-
Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme
NCT00027612 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy
NCT03286335 ·Status: RECRUITING ·Phase: NA
-
Stereotactic Radiation Therapy in Treating Patients With Brain Metastases
NCT00006259 ·Status: COMPLETED ·Phase: PHASE2
-
Focal Intraoperative Radiotherapy of Brain Metastases
NCT03789149 ·Status: TERMINATED ·Phase: PHASE2
-
Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With Radiochemotherapy and Maintenance Chemotherapy in Patients With Glioblastoma (Brain-RF)
NCT06140875 ·Status: RECRUITING ·Phase: NA
-
Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors
NCT00003574 ·Status: COMPLETED ·Phase: PHASE2
-
Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial
NCT02672995 ·Status: UNKNOWN ·Phase: PHASE1
-
Radiation Therapy in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Grade II or Grade III Meningioma
NCT00626730 ·Status: UNKNOWN ·Phase: PHASE2
-
Radiation Therapy With or Without Radiosurgery in Treating Patients With Brain Metastases
NCT00002708 ·Status: COMPLETED ·Phase: PHASE3
-
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
NCT00377156 ·Status: COMPLETED ·Phase: PHASE3